All In Biotech

Drug Trial Radar · NCT06227585

Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

Phase 2/3 Safety and Efficacy Trial of the REVEAL 475 System for Bevonescein-Assisted Intra-Operative Visualization of Nerves in Head and Neck Surgery

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Nov 29, 2023

Primary completion

Oct 24, 2025

Study completion Jan 5, 2026

Sponsor

Lead sponsor
Alume Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Part 1 Phase 2 feasibility study to characterize the feasibility of using the REVEAL 475 system by obtaining surgeon perspective on illumination and ease of use. A Part 2 Phase 3 safety and efficacy study to evaluate conspicuity of the identified nerve due to bevonescein through the use of the Visualization Scoring System (VSS).

Conditions

  • Head and Neck Surgery

Interventions

  • REVEAL 475 SystemDevice

    The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.

  • BevonesceinDrug

    All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Phase 2 Surgeon perspective on REVEAL 475 system blue light illuminationTime frame: Immediately after surgery
  2. Part 1 Phase 2 Surgeon perspective on REVEAL 475 system ease of useTime frame: Immediately after surgery
  3. Part 2 Phase 3 To demonstrate the efficacy of bevonescein to improve the Nerve ConspicuityTime frame: During Surgery
  4. Part 2 Phase 3 To demonstrate the efficacy of bevonescein to improve the Length Measurement of nerves that can be visualizedTime frame: During Surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alume Biosciences

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.